0
Sign In  | Subscribe
6 March 2001, Vol 134, No. 5>
Summaries for Patients | 6 March 2001

The Effect of ACE Inhibitors on Kidney Function in Patients with Type 1 Diabetes FREE

[+] Article and Author Information

The summary below is from the full report titled “Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors? A Meta-Analysis of Individual Patient Data.” It is in the 6 March 2001 issue of Annals of Internal Medicine (volume 134, pages 370-379). The author is the ACE Inhibitors in Diabetic Nephropathy Trialist Group.


Ann Intern Med. 2001;134(5):S86-. doi:10.7326/0003-4819-134-5-200103060-00005
Text Size: A A A

What is the problem and what is known about it so far?

In type 1 diabetes, the pancreas fails to produce insulin, a hormone that regulates the body's ability to store foods. Type 1 diabetes results in high blood sugar levels that can, over time, lead to complications, such as kidney failure. Controlling blood sugar helps prevent these complications. Blood pressure medications called angiotensin-converting enzyme (ACE) inhibitors can also help prevent diabetes-related kidney failure. It is therefore recommended that patients with diabetes take ACE inhibitors when a protein called albumin appears in the urine (albuminuria), a sign of kidney damage. It is unclear, however, whether patients with even very small amounts of albumin in the urine (microalbuminuria) benefit from ACE inhibitors. Previous studies have shown that ACE inhibitors slow kidney damage, but it is not known whether they can actually restore normal kidney function. Lowering blood pressure can by itself protect kidney function, but it is unclear whether ACE inhibitors protect kidney function in diabetic patients by reducing blood pressure or through some other action.

Why did the researchers do this particular study?

To find out whether 1) there is a level of albumin in the urine below which ACE inhibitors show no benefit, 2) ACE inhibitors can help damaged kidneys regain normal function, and 3) improved blood pressure explains the benefit of ACE inhibitors.

Who was studied?

646 patients with type 1 diabetes and microalbuminuria.

How was the study done?

Rather than doing a new study, the researchers used a technique called meta-analysis to combine information from selected previous studies. For a study to be included, patients must have been assigned randomly to receive either an ACE inhibitor, no ACE inhibitor, or a placebo (a pill that looked like an ACE inhibitor but contained no active ingredient) and must have been followed for at least 2 years. Each study also had to include at least 10 patients with normal blood pressure.

What did the researchers find?

The benefit of ACE inhibitors was greatest in patients with larger amounts of microalbuminuria, but patients with very little microalbuminuria also showed benefit. Kidney function was three times more likely to become normal in patients who received ACE inhibitors than in patients who did not receive them. The lowering of blood pressure with ACE inhibitors did not account for all of the improvement in kidney function.

What were the limitations of the study?

This study did not include children and was not designed to look for unfavorable side effects from ACE inhibitors.

What are the implications of the study?

Kidney function improves in patients with type 1 diabetes and microalbuminuria who take ACE inhibitors, regardless of the amount of microalbuminuria and independent of changes in blood pressure.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

Topic Collections
PubMed Articles
Angiotensin-converting enzyme inhibition curbs tyrosine nitration of mitochondrial proteins in the renal cortex during the early stage of diabetes mellitus in rats.
Clinical science (London, England : 1979) Issue date: 2013 Apr
High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.
Seminars in nephrology Issue date: 2012 Sep

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)